Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma.

Fiche publication

Date publication

janvier 2026

Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MANFREDI Sylvain

Tous les auteurs :
Roth GS, Cros J, Neuzillet C, Barbier E, Guarssifi M, Bennacer A, Ducreux M, Muller M, Edeline J, Manfredi S, Williet N, Dusetti N, Laurent-Puig P, Ruffino V, Chanez B, Nicolle R, Taieb J, Malka D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41622055

Résumé

Ampullary adenocarcinoma (AAC) is a rare and aggressive cancer with a 5-year overall survival (OS) rate ranging from 30% to 67% after resection due to a high recurrence rate. Yet, adjuvant therapy's role is still debated. Recent French FFCD-AC cohort study highlighted that adjuvant therapy, can benefit intermediate and high-risk patients. Chemotherapy regimens, include gemcitabine and 5-fluorouracil (5FU) but practices are highly heterogenous due to the low level of evidence. Previous studies suggest that combination chemotherapy, such as mFOLFIRINOX, could offer improved outcomes.